A New Era for Diabetes Care The NTU teams research reflects a broader shift towards precision medicine, tailoring treatments to each patients unique health profileconsidering factors like kidney function, cardiovascular risk, and overall health status
Lillys approval for Mounjaro in Obesity will result in a duopoly in the space, with clinical stage biopharma (mentioned below) likely 2 years from having a drug on the market
this is largely true, but they all generally lack just one or two of themand not the same ones
Some patients report transient symptoms like blurred vision or difficulty focusing, which may resolve on their own
The observed reduction in AUD risk is particularly noteworthy given the global burden of AUD, which affects an estimated 280 million people and is associated with high morbidity and mortality [34]
A retrospective cohort study, found that 4,340 out of 7,043 (62%) of patients taking phentermine for short-term use experienced at least 3% weight loss in 3 months